Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kezar Life Sciences
Biotech
French biotech pens $128M deal for Kezar protein degrader work
French biotech Enodia is paying $1 million upfront in a back-loaded deal for Kezar Life Sciences’ preclinical protein degradation program.
James Waldron
Mar 12, 2026 9:00am
Kezar plans layoffs after FDA axes meeting to discuss next trial
Oct 17, 2025 8:55am
Kezar sees hepatitis hold lifted, mulls restarting lupus program
Jul 16, 2025 8:47am
FDA hits Kezar's zetomipzomib with 2nd clinical hold in 2 months
Nov 13, 2024 5:22am
Kezar rejects Concentra buyout that 'undervalues' the biotech
Oct 17, 2024 9:10am
With Kezar in lupus limbo, Concentra spies potential acquisition
Oct 9, 2024 7:10am
